Zusammenfassung
Die Wirksamkeit von Arsenderivaten bei Neoplasien beruht auf komplexen Mechanismen. Bei der Therapie der akuten Promyelozytenleukämie (APL) steht ein dualer, zur Differenzierung und Apoptose der Blasten führender Effekt im Vordergrund.
Diese Zusammenfassung gibt einen Überblick über Aspekte der Pharmakologie, klinische Effizienz und unerwünschte Effekte von Arsentrioxid (ATO) bei APL. In 17 internationalen Studien zur Primär- und Rezidivtherapie mit ATO wurden insgesamt 565 Patienten eingeschlossen. Von den Patienten mit rezidivierter APL (n = 266) erreichten insgesamt 85,7 % eine Remission bei guter Verträglichkeit von ATO. Das Überleben nach 2 Jahren lag bei 50 bis 77 %. Bei neu diagnostizierter APL (n = 299) wurden Remissionsraten zwischen 73 und 95 % erreicht. Blutungskomplikationen, überwiegend zerebral, umfassten 66 % der Frühtodesfälle und waren die häufigste Todesursache. Die häufigste unerwünschte Begleiterscheinung von ATO war das APL-Differenzierungssyndrom bei bis zu 25 % der Patienten. Bei kurzen Beobachtungszeiten sind Langzeiteffekte noch nicht einschätzbar.
ATO erweist sich als hocheffizient in der Behandlung der APL. Es ist für die rezidivierte und refraktäre APL zugelassen.
Summary
he mechanism of action of arsenic derivates in neoplasitic disease is complex. Cell differentiation and apoptosis are of utmost importance in the therapy of acute promyelocytic leukemia (APL). This review considers essential aspects of the pharmacology, clinical efficacy and adverse effects of arsenic trioxide (ATO) in APL. So far ATO treatment has been investigated in 17 international studies encompassing 565 patients with either initially diagnosed or relapsed APL. 85.7% of patients with relapsed APL (n=266) had a remission and ATO was well tolerated. The overall survival after two years ranged from 50 to 77%. In the initial therapy of APL (n=299), complete remission was achieved in 73 to 95% of patients. The most frequent cause of death (66% of early deaths) was bleeding complications, mostly cerebral bleedings. The most common adverse effect of ATO (in up to 25% of patients) was the APL-differentiation syndrome. Because of the short follow-up periods, long-term effects cannot as yet be evaluated. Arsenic trioxide (ATO) is highly efficacious in the treatment of APL. Its use has been approved for relapsed and refractory APL.
Schlüsselwörter
Arsentrioxid - Promyelozytenleukämie
Key words
arsenic toxide - promyelocytic leukemia
Literatur
-
1
Au W Y, Chim C S, Lie A K, Liang R, Kwong Y L.
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
Br J Haematol.
2002;
117
130-132
-
2
Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H.
Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?.
Br J Haematol.
2001;
112
783-786
-
3
Camacho L H, Soignet S L, Chanel S. et al .
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
J Clin Oncol.
2000;
18
2620-2625
-
4
Carmosino I, Latagliata R, Avvisati G. et al .
Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Haematologica.
2004;
89
615-617
-
5
Chen G Q, Shi X G, Tang W. et al .
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Blood.
1997;
89
3345-3353
-
6
Chou W C, Hawkins A L, Barrett J F, Griffin C A, Dang C V.
Arsenic inhibition of telomerase transcription leads to genetic instability.
J Clin Invest.
2001;
108
1541-1547
-
7
De Botton S, Fawaz A, Chevret S. et al .
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
J Clin Oncol.
2005;
23
120-126
-
8
Degos L, Dombret H, Chomienne C. et al .
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.
Blood.
1995;
85
2643-2653
-
9
Douer D, Hu W, Giralt S, Lill M, DiPersio J.
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
Oncologist.
2003;
8
132-140
-
10
Douer D, Tallman M S.
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
J Clin Oncol.
2005;
23
2396-2410
-
11
Doyle A C.
Notes of a case of leukocythaemia.
Lancet.
1882;
119
490
-
12
Estey E, Garcia-Manero G, Ferrajoli A. et al .
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Blood.
2006;
107
3469-3473
-
13
Forkner C E, Scott T F.
Arsenic as a therapeutic agent in chronic myelogenous leukemia.
JAMA.
1931;
97
3-5
-
14
Frankel S R, Eardley A, Lauwers G, Weiss M, Warrell R P.
The „retinoic acid syndrome” in acute promyelocytic leukemia.
Ann Intern Med.
1992;
117
292-296
-
15
George B, Mathews V, Poonkuzhali B, Shaji R V, Srivastava A, Chandy M.
Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience.
Leukemia.
2004;
18
1587-1590
-
16
Ghavamzadeh A, Alimoghaddam K, Ghaffari S H. et al .
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Ann Oncol.
2006;
17
131-134
-
17
Helwig A, Klemm M, Schuttig R. et al .
Arsenic-induced APL differentiation in cerebrospinal fluid.
Leuk Res.
2006;
, Epub ahead of print
-
18
Jing Y, Wang L, Xia L. et al .
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
Blood.
2001;
97
264-269
-
19
Kai T, Kimura H, Shiga Y, Ogawa K, Sato H, Maruyama Y.
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy.
Int J Hematol.
2006;
83
337-340
-
20
Kwong Y L, Au W Y, Chim C S, Pang A, Suen C, Liang R.
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Am J Hematol.
2001;
66
274-279
-
21
Lazo G, Kantarjian H, Estey E, Thomas D, O’Brien S, Cortes J.
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Cancer.
2003;
97
2218-2224
-
22
Lengfelder E, Gnad U, Büchner T, Hehlmann R.
Treatment of relapsed acute promyelocytic leukemia.
Onkologie.
2003;
26
373-379
-
23
Lengfelder E, Hehlmann R, Büchner T.
Aktuelle Therapiekonzepte bei akuter Promyelozytenleukämie.
Dtsch Med Wochenschr.
2001;
126
1073-1079
-
24
Lengfelder E, Saussele S, Weisser A, Büchner T, Hehlmann R.
Treatment concepts of acute promyelocytic leukemia.
Crit Rev Oncol Hematol.
2005;
56
261-274
-
25
Leoni F, Gianfaldoni G, Annunziata M. et al .
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Haematologica.
2002;
87
485-489
-
26
Lu D P, Qiu J Y, Jiang B. et al .
Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report.
Blood.
2002;
99
3136-3143
-
27
Mathews V, George B, Lakshmi K M. et al .
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.
Blood.
2006;
107
2627-2632
-
28
Miller W H, Schipper H M, Lee J S, Singer J, Waxman S.
Mechanisms of action of arsenic trioxide.
Cancer Res.
2002;
62
3893-3903
-
29
Niu C, Yan H, Yu T. et al .
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Blood.
1999;
94
3315-3324
-
30
Ohnishi K, Yoshida H, Shigeno K. et al .
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Leukemia.
2002;
16
617-622
-
31
Raffoux E, Rousselot P, Poupon J. et al .
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
J Clin Oncol.
2003;
21
2326-2334
-
32
Roboz G J, Dias S, Lam G. et al .
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.
Blood.
2000;
96
1525-1530
-
33
Sanz M A, Arcese W, de la Rubia J. et al .
Stem cell transplantation for acute promyelocytic leukemia in the ATRA era: A survey of the European Blood and Marrow Transplantation Group.
Blood.
2000;
96
522a
-
34
Sanz M A, Fenaux P, LoCoco F.
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Haematologica.
2005;
90
1231-1235
-
35
Shen Y, Shen Z X, Yan H. et al .
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Leukemia.
2001;
15
735-741
-
36
Shen Z X, Chen G Q, Ni J H. et al .
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Blood.
1997;
89
3354-3360
-
37
Shen Z X, Shi Z Z, Fang J. et al .
All-trans retinoic acid/ As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
Proc Natl Acad Sci U S A.
2004;
101
5328-5335
-
38
Shigeno K, Naito K, Sahara N. et al .
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Int J Hematol.
2005;
82
224-229
-
39
Siu C W, Au W Y, Yung C. et al .
Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety.
Blood.
2006;
108
103-106
-
40
Soignet S L, Frankel S R, Douer D. et al .
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
J Clin Oncol.
2001;
19
3852-3860
-
41
Soignet S L, Maslak P, Wang Z G. et al .
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
N Engl J Med.
1998;
339
1341-1348
-
42
Tallman M S, Nabhan C, Feusner J H, Rowe J M.
Acute promyelocytic leukemia: evolving therapeutic strategies.
Blood.
2002;
99
759-767
-
43
Thomas X, Dombret H, Cordonnier C. et al .
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Leukemia.
2000;
14
1006-1013
-
44
Thomas X, Pigneux A, Raffoux E, Huguet F, Caillot D, Fenaux P.
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Haematologica.
2006;
91
996-997
-
45 Trisenox. Summary of Product Characteristics 2002;. Cell Therapeutics Europe 5
-
46
Tsimberidou A M, Estey E, Whitman G J. et al .
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Leuk Res.
2004;
28
991-994
-
47
Unnikrishnan D, Dutcher J P, Varshneya N. et al .
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Blood.
2001;
97
1514-1516
-
48
Wang Z, Zhou J, Lu X, Gong Z, Le X C.
Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Chem Res Toxicol.
2004;
17
95-103
-
49
Westervelt P, Brown R A, Adkins D R. et al .
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Blood.
2001;
98
266-271
-
50
Zhang P, Wang S, Hu L. et al .
Seven years’ summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide - an analysis of 242 cases.
Zhonghua Xue Ye Xue Za Zhi.
2000;
21
67-70
-
51
Zhu J, Koken M H, Quignon F. et al .
Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia.
Proc Natl Acad Sci U S A.
1997;
94
3978-3983
Priv.-Doz. Dr. Eva Lengfelder
III. Medizinische Universitätsklinik Mannheim
Wiesbadener Straße 7-11
68305 Mannheim
Phone: +49/621/3834110
Fax: +49/621/3834201
Email: eva.lengfelder@med3.ma.uni-heidelberg.de
